Bernd Bhatt

Bernd Bhatt has contributed to the clinical implementation of radioligand therapy programs at one of Europe's leading nuclear medicine centers, focusing on standardization of treatment protocols, dosimetry optimization, and quality assurance for therapeutic radiopharmaceuticals. His work has helped establish best practices for Lu-177 PSMA-617 administration including patient preparation, post-treatment radiation safety, and response assessment criteria. He has participated in multi-center clinical trials evaluating radioligand therapies across tumor types and contributed to developing educational frameworks for training nuclear medicine physicians in theranostic approaches. His clinical expertise bridges the gap between radiopharmaceutical development and routine clinical practice.